Exploratory research for consideration of virus inhibitory effect, safety and optimal dose of nafamostat mesilate in early mild COVID-19 patients

Okugawa Shu0 个研究点目标入组 30 人开始时间: 2021年7月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients who have given written consent to participate in the study
•2)SARS-CoV-2 PCR Positive
•3) Patients in need of inpatient treatment
•4)Patents with no obvious pneumonia on chest images
•5)Patients who are hospitalized and can start study drug administration within 5days after the onset of COVID-19 symptoms

•1)Patients with recurrence or reinfection of COVID-19
•2) Patients who are asymptomatic or whose onset date of various symptoms due to COVID-19 cannot be specified
•3) Patients suspected of having infection with microorganisms other than SARS-CoV-2 requiring treatment
•4) Patients with hyperkalemia or hyponatremia
•5) Patients undergoing or planning treatment for malignant tumors
•6) Patients with severe liver dysfunction or renal dysfunction requiring dialysis
•7) Patients with impaired consciousness such as disorientation
•8)Patients who are pregnant or who may be pregnant
•9) Patients with weakened immune system
•10)Patients with a history of hypersensitivity to Nafamostat Mesilate
•11)Patients who are considered inappropriate for inclusion in the study by the investigator

发起方

Okugawa Shu